Huay Cheem Tan
Vorsitzender bei Singapore Heart Foundation
Profil
Huay Cheem Tan is currently the Chairman of the Singapore Heart Foundation and a Professor at the Yong Loo Lin School of Medicine.
He previously served as an Independent Non-Executive Director at HeMo (China) Bioengineering Co., Ltd.
and held the position of President at the Singapore Cardiac Society from 2003 to 2005 and the Asian Pacific Society of Interventional Cardiology from 2014 to 2019.
Tan received his graduate degree from the National University of Singapore in 1992.
Aktive Positionen von Huay Cheem Tan
Unternehmen | Position | Beginn |
---|---|---|
Yong Loo Lin School of Medicine | Corporate Officer/Principal | - |
Singapore Heart Foundation | Vorsitzender | - |
Ehemalige bekannte Positionen von Huay Cheem Tan
Unternehmen | Position | Ende |
---|---|---|
Asian Pacific Society of Interventional Cardiology | Präsident | 01.01.2019 |
Singapore Cardiac Society | Präsident | 01.01.2005 |
HeMo (China) Bioengineering Co., Ltd.
HeMo (China) Bioengineering Co., Ltd. Information Technology ServicesTechnology Services HeMo Bioengineering Ltd. operates as a medical device company. Its portfolio of neuro-interventional medical devices covers all of the ischemic stroke, hemorrhagic stroke and neuro access fields. The company was founded in June 21, 2017 and is headquartered in Weihai, China. | Direktor/Vorstandsmitglied | - |
Ausbildung von Huay Cheem Tan
National University of Singapore | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Singapore Heart Foundation | |
Singapore Cardiac Society | |
HeMo (China) Bioengineering Co., Ltd.
HeMo (China) Bioengineering Co., Ltd. Information Technology ServicesTechnology Services HeMo Bioengineering Ltd. operates as a medical device company. Its portfolio of neuro-interventional medical devices covers all of the ischemic stroke, hemorrhagic stroke and neuro access fields. The company was founded in June 21, 2017 and is headquartered in Weihai, China. | Technology Services |
Asian Pacific Society of Interventional Cardiology |